Shares of Versartis (NASDAQ:VSAR) have earned a consensus rating of “Hold” from the twelve brokerages that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, ten have assigned a hold recommendation and one has issued a buy recommendation on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $5.13.
VSAR has been the topic of several analyst reports. Zacks Investment Research downgraded Versartis from a “hold” rating to a “sell” rating in a report on Sunday, January 21st. ValuEngine upgraded Versartis from a “strong sell” rating to a “sell” rating in a report on Monday, April 2nd. Finally, Canaccord Genuity downgraded Versartis from a “buy” rating to a “hold” rating and lowered their price target for the company from $9.00 to $5.00 in a report on Friday, March 2nd.
Hedge funds have recently made changes to their positions in the business. Deutsche Bank AG boosted its position in shares of Versartis by 90.0% in the fourth quarter. Deutsche Bank AG now owns 82,299 shares of the biopharmaceutical company’s stock valued at $180,000 after acquiring an additional 38,975 shares during the period. Two Sigma Advisers LP boosted its position in shares of Versartis by 63.9% in the fourth quarter. Two Sigma Advisers LP now owns 155,700 shares of the biopharmaceutical company’s stock valued at $343,000 after acquiring an additional 60,700 shares during the period. Delek Group Ltd. bought a new stake in shares of Versartis in the fourth quarter valued at approximately $145,000. GSA Capital Partners LLP boosted its position in shares of Versartis by 82.1% in the first quarter. GSA Capital Partners LLP now owns 159,500 shares of the biopharmaceutical company’s stock valued at $263,000 after acquiring an additional 71,900 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in shares of Versartis by 13.6% in the first quarter. Dimensional Fund Advisors LP now owns 617,702 shares of the biopharmaceutical company’s stock valued at $1,019,000 after acquiring an additional 73,754 shares during the period. Institutional investors own 48.25% of the company’s stock.
Versartis remained flat at $$1.55 during mid-day trading on Friday, Marketbeat reports. The company had a trading volume of 353 shares, compared to its average volume of 484,583. Versartis has a 12-month low of $1.55 and a 12-month high of $1.55. The firm has a market capitalization of $54.12 million, a P/E ratio of -0.64 and a beta of 2.10. The company has a quick ratio of 21.29, a current ratio of 21.29 and a debt-to-equity ratio of 0.09.
Versartis (NASDAQ:VSAR) last announced its quarterly earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.61. equities analysts predict that Versartis will post -3.15 earnings per share for the current year.
Receive News & Ratings for Versartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis and related companies with MarketBeat.com's FREE daily email newsletter.